Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
Q4 2024 Earnings Call Transcript March 12, 2025 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.18, ...
Gross profit for 2024 dropped to $0.5 million ... previously expensed to research and development expenses prior to FDA approval of the 365-day product. Fourth quarter 2024 selling, general ...
Dr. Dennis Gross’ SpectraLite FaceWare Pro mask stood out to me because it looked like something Beyoncé would’ve worn on her Renaissance tour—and it's FDA-approved to treat acne and ...
The U.S. Food and Drug Administration (FDA) approved Emrosi™ in November 2024, with a market launch expected in early spring of 2025. This approval comes as the company faces revenue challenges ...
Total Revenue of $426.5 Million, a 65% YoY IncreaseFY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation ...
Financial income, net for the fourth quarter of 2024 was $252,000, a decrease of $216,000 or 46.1% compared to $468,000 for the fourth quarter of 2023. This decrease was primarily due to less interest ...